Gilead, As­traZeneca/Dai­ichi Sankyo of­fer first look at TROP2 AD­Cs in first-line lung can­cer as ri­val­ry heats up 

Pre­lim­i­nary mid-stage da­ta from two ri­val TROP2-tar­get­ing AD­Cs ad­vanced by As­traZeneca/Dai­ichi Sankyo and Gilead, com­bined with im­mune check­point in­hibitors, have pro­vid­ed a first glance at the risk-ben­e­fit bal­ance of this ap­proach in non-small cell lung can­cer. And al­though Gilead no­ticed a slight­ly high­er re­sponse rate, an­a­lysts called the re­sults “broad­ly sim­i­lar.”

Both As­traZeneca’s Da­to-DXd and Gilead’s Trodelvy com­prise an an­ti­body that tar­gets the TROP2 re­cep­tor linked with a DNA topoi­so­merase 1 in­hibitor. Da­to-DXd is an in­ves­ti­ga­tion­al pro­gram in Phase III for breast can­cer and NSCLC, while Trodelvy is ap­proved as a sin­gle agent for cer­tain forms of breast can­cer and has won ac­cel­er­at­ed ap­proval for blad­der can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER